Trial of a virus treatment for tumors that came back
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 1 study tests STI-1386, an oncolytic (tumor-fighting) virus, for solid tumors that have relapsed or do not respond to treatment. It mainly checks safety, and also looks for early signs of how well it may work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor outside the brain that has relapsed or is not responding to prior treatment
- You have at least one measurable tumor spot that a scan can track
- You are well enough to do daily activities (ECOG status 2 or better)
- Your expected lifespan is at least 3 months, and key blood, liver, and kidney tests are adequate
- You have recovered from previous treatment side effects to mild levels (grade 2 or less)
- You are able to follow the study schedule and agree to contraception rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This Phase 1 study tests SB17170 in people with solid tumors that have spread or grown despite standard treatments. It looks for safety and early signs of how well the drug might work when other options have failed.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.